DUBLIN, Ireland, October 18, 2019 – Medtronic, the global leader in medical technology, yesterday announced the launch of GI Genius™ intelligent endoscopy module at UEG Week in Barcelona, Spain. The GI Genius™ module is the first system worldwide using artificial intelligence to detect colorectal polyps. It provides physicians with a powerful new solution in the fight against colorectal cancer.
The GI Genius module uses advanced artificial intelligence to highlight the presence of pre-cancerous lesions with a visual marker in real-time – serving as an ever vigilant second observer. Studies have shown that having a second observer can increase polyp detection rates; every 1 percent increase in adenoma detection rate reduces the risk of colorectal cancer by 3 percent.1 Colorectal cancer (CRC) is the third most common form of cancer globally with 1.8 million new cases every year.2
“One of the key factors to maximizing the prevention of colorectal cancer is the integration of advanced technologies like artificial intelligence into daily practice. The use of artificial intelligence in gastroenterology ushers in a new era of diagnostic endoscopy that can improve the quality of colonoscopies. In my experience, the GI Genius module can be extremely precise in identifying lesions in the colonic mucosa that can be difficult to detect and may have been missed. This change in daily practice has the potential to improve diagnosis and overall outcomes for patients that may have colorectal cancer”, said Prof. Alessandro Repici, head of gastroenterology at Humanitas Hospital in Rozzano (Milan).
“Medtronic is focused on preventing colorectal cancer by early detection of pre-cancerous polyps with AI-assisted technologies,” said Giovanni Di Napoli, vice president and general manager of the Gastrointestinal & Hepatology business, which is part of the Minimally Invasive Therapies Group at Medtronic. “The GI Genius module automatically detects polyps, including small flat polyps that may go undetected thus increasing accuracy and reducing the risk of interval cancers which can occur between colonoscopies.”
To bring this technology to market, Medtronic entered into a worldwide distribution agreement with Cosmo. Cosmo is the sole manufacturer of the artificial intelligent software and device. GI Genius intelligent endoscopy module is CE-marked and is available in select European markets. GI Genius intelligent endoscopy module does not have FDA clearance and therefore is not available for sale in the United States.
_____________
1.Corley DA, Jenson CD, Marks AR JR, et al. NEJM 2014;370:1298-306.
2. http://www.crcprevention.eu/index.php?pg=colorectal-cancer-epidemiology
About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused in treating selected Gastrointestinal Disorders and Endoscopy. The Company’s proprietary clinical development pipeline specifically addresses innovative treatments for IBD, Colonic Infections and detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has recently entered into a partnership with Medtronic for the global distribution of its novel Artificial Intelligence device to be used in coloscopies and GI procedures. Further, Cosmo is the licensee for US of the novel agent for procedural sedation, Remimazolam. For additional information on Cosmo and its products please visit the Company’s website: www.cosmopharma.com
Calendar
| Credit Suisse Small & Mid Cap Conference | Zurich November 13, 2019 |
| Jefferies Global Health Care Conference | London November 20, 2019 |
| FY Results | March 2020 |
| Annual General Meeting | May 2020 |
Contact:
Niall Donnelly, Chief Financial Officer & Head of Investor Relations
Cosmo Pharmaceuticals N.V.
Tel: +353 1 817 03 70
ndonnelly@cosmopharma.com
Disclaimer
Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.
This communication is not an offer of securities of any issuer. Securities may not be offered or sold in the United States absent registration or an exemption from the registration requirement of the US Securities Act of 1933.
This press release constitutes neither an offer to sell nor a solicitation to buy securities and it does not constitute a prospectus within the meaning of article 652a and/or 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange or any similar document. The offer will be made solely by means of, and on the basis of, a securities prospectus to be published. An investment decision regarding the securities to be publicly offered should only be made on the basis of the securities prospectus.
This press release is made to and directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), and (iii) high net worth individuals, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order. Any person who is not a relevant person should not act or rely on this press release or any of its contents.
This press release does not constitute an “offer of securities to the public” within the meaning of Directive 2003/71/EC of the European Union (the “Prospectus Directive”) of the securities referred to in it (the “Securities”) in any member state of the European Economic Area (the “EEA”). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.